What is Exelixis's less than 12 months?

Exelixis (EXEL) reported less than 12 months of $480.39M in Q1 2026.

How has Exelixis's less than 12 months changed year-over-year?

Exelixis's less than 12 months increased by 64.0% year-over-year, from $292.88M to $480.39M.

What is the long-term trend for Exelixis's less than 12 months?

Over 2 years (2023 to 2025), Exelixis's less than 12 months has grown at a -62.7% compound annual growth rate (CAGR), from $419.3M to $58.2M.

Exelixis EXEL Less than 12 months

Less than 12 months at other companies

Ionis PharmaceuticalsIONS

——

Gilead SciencesGILD

——

ModernaMRNA

——

Other financials

Income statement

See full

Revenue$610.8M+10.0%

Gross profit$590.9M+10.2%

Operating income$251.3M+34.5%

Net income$210.5M+31.9%

EPS (diluted)$0.79+43.6%

Balance sheet

See full

Cash & equivalents$226.2M+23.1%

Total debt$169.5M-9.4%

Total equity$1.9B-9.2%

Total assets$2.6B-8.6%

Cash flow

See full

Operating cash flow$251.8M+19.1%

CapEx$1.5M-48.9%

Free cash flow$250.3M+20.1%

Valuation

See full

Market cap$13.05B+10.1%

Enterprise value$12.99B+9.5%

P/E15.7×-2.8×

P/S5.5×+0.3×

Profitability

See full

Gross margin96.4%-0.3pp

Operating margin39.4%+6.3pp

Net margin35.1%+7.1pp

FCF margin38.6%+2.9pp

Returns & leverage

See full

Return on equity41%+10.8pp

Debt / equity0.1×0.0×

Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's less than 12 months.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Exelixis's less than 12 months?: Exelixis (EXEL) reported less than 12 months of $480.39M in Q1 2026.
How has Exelixis's less than 12 months changed year-over-year?: Exelixis's less than 12 months increased by 64.0% year-over-year, from $292.88M to $480.39M.
What is the long-term trend for Exelixis's less than 12 months?: Over 2 years (2023 to 2025), Exelixis's less than 12 months has grown at a -62.7% compound annual growth rate (CAGR), from $419.3M to $58.2M.